Scholarlink

Purpose <p>“Biopsy-only” glioblastoma (BO-GB) is an understudied entity associated with a poor outcome for whom quality of life preservation is essential. Our objective was to define and determine the time of autonomy duration in BO-GB and its potential predictive factors.</p> Methods <p>Patients diagnosed with IDH wild-type BO-GB and enrolled in a prospective regional cohort from 2014 to 2017 were analyzed for their clinical features, functional status, histo-molecular profile, neuroimaging findings, and treatment details.</p> Results <p>137 patients were included in the present analysis. Median age at inclusion was 66 years old and median KPS was 70. Median time of autonomy duration was 7.7 months (CI95%: 5.6–9.7). In the radiotherapy – temozolomide subgroup, median time of autonomy duration was 9.1 months (CI95%: 8.1–10.3); in the chemotherapy upfront group, median time of autonomy duration was 5.3 months (CI95%: 3.5–7.1). Autonomy duration was correlated to patient age and overall survival but not with initial functional status. Among the 65 patients with KPS &lt; 70 at baseline, 11 patients (16.9%) restored their autonomy under treatment. Autonomy duration was not different between these 11 patients and the patients with baseline KPS ≥ 70 (<i>p</i> = 0.758).</p> Conclusion <p>Autonomy duration may serve as a surrogate endpoint for overall survival for BO-GB patients and may be included in future clinical trials dedicated to this frail population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas

  • 期刊论文

  • 发表日期：

    2025年10月16日

查看全文
  • Vincent Harlay,
  • Céline Bequet,
  • Romain Appay,
  • Alexandre Bertucci,
  • Gregorio Petrirena,
  • Chantal Campello,
  • Maryline Barrié,
  • Didier Autran,
  • Thomas Graillon,
  • Henry Dufour,
  • Dominique Figarella-Branger,
  • Laetitia Padovani,
  • Anne Barlier,
  • Isabelle Nanni,
  • Emeline Tabouret,
  • Olivier Chinot

摘要

Purpose

“Biopsy-only” glioblastoma (BO-GB) is an understudied entity associated with a poor outcome for whom quality of life preservation is essential. Our objective was to define and determine the time of autonomy duration in BO-GB and its potential predictive factors.

Methods

Patients diagnosed with IDH wild-type BO-GB and enrolled in a prospective regional cohort from 2014 to 2017 were analyzed for their clinical features, functional status, histo-molecular profile, neuroimaging findings, and treatment details.

Results

137 patients were included in the present analysis. Median age at inclusion was 66 years old and median KPS was 70. Median time of autonomy duration was 7.7 months (CI95%: 5.6–9.7). In the radiotherapy – temozolomide subgroup, median time of autonomy duration was 9.1 months (CI95%: 8.1–10.3); in the chemotherapy upfront group, median time of autonomy duration was 5.3 months (CI95%: 3.5–7.1). Autonomy duration was correlated to patient age and overall survival but not with initial functional status. Among the 65 patients with KPS < 70 at baseline, 11 patients (16.9%) restored their autonomy under treatment. Autonomy duration was not different between these 11 patients and the patients with baseline KPS ≥ 70 (p = 0.758).

Conclusion

Autonomy duration may serve as a surrogate endpoint for overall survival for BO-GB patients and may be included in future clinical trials dedicated to this frail population.